EBITDA: Income before interest, taxes, depreciation and amortization.
NRx Pharmaceuticals, Inc. (NRXP) had EBITDA of $-3.73M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-17.58M |
|
-- |
|
-- |
|
$3.73M |
|
$-3.73M |
|
$-13.86M |
|
$-17.58M |
|
$-17.58M |
|
$-17.58M |
|
$-17.58M |
|
$-17.58M |
|
$-17.58M |
|
$-3.73M |
|
|
EBITDA |
$-3.73M |
17.93M |
|
17.93M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$4.59M |
|
-- |
|
$0.25M |
|
$4.84M |
|
$40.45M |
|
-- |
|
-- |
|
$40.45M |
|
$-35.62M |
|
$-35.62M |
|
$-35.62M |
|
19.47M |
|
| Cash Flow Statement Financials | |
$-7.51M |
|
-- |
|
$8.97M |
|
$1.44M |
|
$2.91M |
|
$1.47M |
|
$0.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.11 |
|
-- |
|
-- |
|
-- |
|
-0.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.51M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
49.36% |
|
49.36% |
|
-363.39% |
|
49.36% |
|
$-1.83 |
|
$-0.42 |
|
$-0.42 |
|